摘要
目的讨论并分析在慢性阻塞性肺病急性加重期治疗中,全身应用甲强龙联合尼可刹米的临床效果。方法选取2011年3月至2012年2月四川省江安县中医医院收治的60例慢性阻塞性肺病患者。采用随机分组的方式将患者分为观察组和对照组,观察组行全身应用甲强龙联合尼可刹米治疗,对照组行常规治疗。结果经过系统治疗,观察组患者第一秒用力呼气容积(FEV1)/用力肺活量(FVC)和FEV1均要明显优于对照组,差异有统计学意义(P<0.05)。结论在慢性阻塞性肺病急性加重期的治疗中,全身应用甲强龙联合尼可刹米具有一定的临床价值。
Objective To discuss and analyze the treatment in the acute aggravating period of chronic obstructive pulmonary disease(COPD), systemic application of the clinical effect of combination of methylprednisolone and nikethamide. Methods From March 2011 to February 2012, 60 patients with COPD were selected in Jiangan hospital of traditional Chinese medicine of Anxian county. With the method of randomized patients divided into observation group and control group, the observation group line systemic application of combination of methylprednisolone and nikethamide treatment, control group routine treatment. Results After treatment system, patients with FEV1/FVC and FEV1 observation group were significantly better than the control group, the difference was statistically significant(P<0.05). Conclusion In the treatment of acute aggravating period of COPD, systemic application of combination of methylprednisolone, brake m has a certain clinical value.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2015年第S1期49-50,共2页
Chinese Journal of Practical Internal Medicine
关键词
尼可刹米
慢性阻塞性肺病
临床效果
nikethamide
chronic obstructive pulmonary disease
clinical effect
